Work

Lowering pain and inflammation drug costs: Evaluating the impact of the Mark Cuban Cost Plus drug company model on Medicare savings

Year: 2025

Type: article

Abstract: Background: Pain and inflammation are among the most prevalent and debilitating conditions affecting Medicare beneficiaries, with 78% reporting chronic pain and nearly half relying on medications like NSAIDs, acetaminophen, and anticonvulsants for management. These conditions necessitate long-term pharmaceutical interventions, contributing significantly to the rising costs within Medicare Part D, which covers prescription drugs for over 80% of beneficiaries. Current pricing structures and the inability to negotiate prices exacerbate the financial strain on this demographic, leading to high out-of-pocket expenses and reduced medication adherence. This study examines the potential of the Mark Cuban Cost Plus Drug Company (MCCPDC) pricing model to address these challenges by providing affordable alternatives for pain and inflammation medications.

Source: SHAREOK (University of Oklahoma; Oklahoma State University; Central Oklahoma University)

Authors: Rowsey, Kaylyn, Khan, Adam, Brassfield, Jillian, Rashid, Matthew, Duncan, Jacob, Vassar, Matt

Language: English

Topic: Pharmaceutical Economics and Policy

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W7110575531

FWCI:

Cites:

Cited by:

Related to: